Glycine transporter (GlyT1) function is typically measured by radiolabeled glycine uptake using lysis methods or scintilla tion proximity assays (SPAs), which have limited throughput. This study shows the adaptation of the standard cell lysis method to a screening assay with improved throughput and assay characteristics. The assay takes advantage of the 384well format, standard laboratory automation, and cryopreserved CHOK1 cells stably overexpressing human GlyT1a transporter (CHOK1/hGlyT1a) that were validated and banked in advance of screening. The assay was evaluated for the time course of glycine uptake, K m , V max , Z′ factor analysis, and IC 50 value determination with reference GlyT1 inhibitors. Screening of 118,000 compounds at 10 mM identified 4556 compounds (3.9%) as inhibitors. Positive compounds (>50% inhibition) were retested in the assay at 4 inhibitor concentrations. Compounds demonstrating greater than 40% inhibition at 10 mM were considered as confirmed positives, yielding a 68% confirmation rate from the original screen. To eliminate compounds that nonspecifically inhibited glycine uptake, IC 50 values were determined in both GlyT1 and GlyT2 assays, and those com pounds that inhibited GlyT2 were removed from consideration. The screening campaign identified 300 small molecules as selective GlyT1 inhibitors for lead optimization, demonstrating the utility of this costeffective method. (Journal of Biomolecular
INTRODUCTION
S chizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symp toms and a high rate of comorbid depression. Although current treatments using both typical and atypical antipsychotics have beneficial effects on positive symptoms, there are significant adverse effects associated with use of these drugs. 1, 2 Develop ment of therapeutics that target cognitive and negative symp tom domains with improved side effect profiles is an area of intensive research. 3, 4 It has been proposed that hypofunction of NmethylDaspartate receptors (NMDARs) contributes to the pathology of schizophrenia. 5, 6 This hypothesis is supported by the observation that phencyclidine (PCP) and ketamine, which are antagonists of the NmethylDaspartate (NMDA) gluta mate receptor subtype, induce a psychotic state in humans that faithfully mimics the symptoms of schizophrenia. 7 Given the implication of NMDA hypofunction in schizophrenia, com pounds that potentiate glutamatergic transmission would be expected to provide benefit additional to that provided by antipsychotics. 8 One approach to potentiate NMDAR activity involves inhibiting the clearance of synaptic glycine. 9, 10 Glycine plays dual roles as a neurotransmitter, operating at both glycinergic, strychninesensitive synapses and as an obligate coagonist of NMDAR at the strychnineinsensitive Gly B site, where it poten tiates activity by increasing the frequency of channel opening. 11 Regulation and removal of synaptic glycine concentration are achieved by 2 Na + /Cldependent glycine transporters, GlyT1 (SLC6A9) and GlyT2 (SLC6A5). GlyT1 is localized primarily to astrocytes in caudal brain regions at glycinergic synapses and forebrain regions, where the transporter colocalizes with the NMDA receptor. 12, 13 GlyT2 is a subtype that shares approx imately 50% amino acid homology with GlyT1. 14 A role for this transporter has been suggested in recycling glycine from gly cinergic synapses and maintaining glycine content in synaptic vesicles. 15 Screening of compound libraries for GlyT1 inhibitors has proceeded through the use of binding assays, 13, 16 as well as functional glycine uptake assays 17 and fluorescent imaging plate reader (FLIPR) membrane potential assays. 18, 19 Typically, a cellbased functional assay is employed to follow uptake of radiolabeled glycine into cells that express the transporter endogenously or in cells that express recombinant human trans porter. Assay throughput is low due to the use of 96well plates and several wash steps. 20 A homogeneous version of the radio labeled uptake assay has been reported using a platebased scintillation proximity assay (SPA) but is typically used in 96 well format. 17, 21 An alternative screening approach takes advan tage of the fact that uptake through GlyT1 induces a current that changes the membrane potential, which can be detected with a fluorescent dye using FLIPR. FLIPR assays have been evaluated for highthroughput screening (HTS) campaigns for GlyT1 and GlyT2. 18, 19 The calculated Z′ factor value was 0.66 for GlyT1 but was marginal (0.42) for GlyT2. The confirma tion of hits for GlyT2 screening data was reported to be low, whereas no screening data results were reported for the GlyT1 FLIPR assay.
The radiolabeled glycine uptake assay was adapted to a 384 well format assay using standard laboratory automation. This assay is affordable, robust, and reproducible and can be used to identify inhibitors of GlyT1 from a large compound library. In addition, the assay could be used to generate IC 50 value determi nations for large numbers of compounds, which confirmed iden tification of inhibitor compounds from the screening campaign.
Parts of this work have been published previously in abstract form. 22 
MATERIALS AND METHODS
GlyT1 reference inhibitors ALX5407 and sarcosine were obtained from SigmaAldrich (St. Louis, MO). SSR504734 was prepared by the Medicinal Chemistry group at Cephalon as described. 23 [ 3 H]Glycine (56 Ci/mmol) was obtained from PerkinElmer (Shelton, CT).
CLONING AND STABLE CELL DEVELOPMENT
Fulllength human GlyT1a was PCRamplified from human adult female brain (78060141; Stratagene, La Jolla, CA) and shuttled into the pIRESpuro3 mammalian expression vector (Clontech, Mountain View, CA). The final expression construct was sequence verified and contained the entire GlyT1a coding region, homologous to GenBank Acc NM_001024845, positions 2432144. The predicted protein sequence was identical to GenBank DNA files Accession CAI19430.1 and NP_001020016.1. After sequence verification, the EndoFree ® Plasmid Maxi Kit (Qiagen, Valencia, CA) was used to prepare endotoxinfree plasmid DNA for transfection.
A parental CHOK1 cell line (CCL61; ATCC, Manassas, VA) was transfected with the pIRESpuro3GlyT1a vector using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA). The trans fected cells were diluted 24 h after transfection, and antibiotic selection of a stable pool was initiated by culture in Dulbecco's modification of Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM glutamine, and 7 mg/mL puro mycin. The stable pool was expanded under selection pressure for 12 days, and clones were isolated by limiting dilution at a concentration of 0.3 cells/well in a 96well plate. Sixteen clones were assayed for glycine uptake, and 6 clones were selected for further validation. One clone was selected for use in HTS based on kinetic and pharmacological parameters. To obtain sufficient quantities of cells for screening, the selected clone was scaled up over 3 passages to prepare 8 × 10stack CellSTACK ® chambers (Corning, Corning, NY). Cells were harvested (7 × 10 9 cells) and aliquoted into cryogenic tubes at 2 × 10 7 cells/mL in 10% (v/v) DMSO in culture media without puromycin. Cells were frozen at -70 °C in Nalgene Cryo 1 °C freezing containers (Thermo Fisher Scientific, Rochester, NY) and stored in liquid nitrogen.
[ 3 H]GLYCINE UPTAKE ASSAY (LYSIS METHOD)
Compounds were prepared in advance by spotting 1 mL from library plates (4 mM stocks in DMSO) directly into 384well polypropylene plates (Nunc, Thermo Fisher Scientific). Plates were placed in StoragePods™ (The StoragePod™, Surrey, UK) containing an inert and dry nitrogen environment and stored at -20 °C until used in screening.
Culturetreated, optical bottom 384well Nunc plates (142762) were bar coded on an open bench prior to seeding cells. Frozen stocks of CHOK1/hGlyT1a cells were thawed and plated at a density of 10,000 cells per well and incubated overnight in a humidified cell incubator held at 37 °C with a 10% CO 2 atmosphere. Optimization of cell density was deter mined as previously described. 22 Cell plating was automated using a Multidrop (Thermo Scientific, Waltham, MA) dispen ser with an autoclaved cassette. When 96well plates were used, cells were plated at a density of 40,000 cells/well in Costar 3610 plates. The CHO cells are rated as Biosafety Level 1, which was ideal for use in the open lab, and instrumentation was not generally used under a biosafety cabinet.
The following steps were automated using the SAMI FX Work Station (Beckman Coulter, Fullerton, CA), which con tained an integrated ELx405 CW™ plate washer (BioTek, Winooski, VT), Cytomat ® 2 C cell incubator, and Cytomat ® Microplate Hotel (Thermo Scientific). The culture medium was removed from cells, and wells were washed by 6 exchanges with glycine uptake buffer (120 mM NaCl, 2 mM KCl, 0.1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 5 mM alanine, pH 7.5, using 1M TRIS base), with 120 mL dispensed and 100 mL aspirated with each exchange. The distance from the aspiration tubes to the well bottom was 6 mm and 12 mm during aspira tion and dispensing, respectively. The residual wash volume (20 mL) created sufficient distance from the aspiration tubes on the washer to eliminate cell loss during this step, and 6 buffer exchanges produced consistent background counts. Less wash ing would be required for cells that remain tightly adhered to the well surface because all residual wash volume could be remo ved. Residual wash volume was completely removed from the wells using a very slow aspiration on the Biomek, and 40 mL per well of glycine uptake buffer was added. Wash and aspira tion manipulations did not disturb the lawn of cells as deter mined by inspection of random wells under a light microscope. Intermediate dilutions of compounds were prepared by adding 39 mL of glycine uptake buffer to the spotted compound, and 5 mL of this dilution was added to the assay and incubated for 20 min at 27 °C in the cell incubator. The screening concentra tion for test compounds was 10 mM, and DMSO concentration was maintained at 0.5% in all test and control wells. DMSO concentrations above 0.5% resulted in a loss of greater than 20% of the glycine uptake activity observed in the absence in DMSO. 22 Each screening plate also contained positive (0.5% DMSO in buffer), negative (8 mM sarcosine), and reference GlyT1 inhibitor controls ((S,S)SSR504734 at 100 nM). A 10× glycine stock (5 mL) was added to the wells to achieve a final concentration of 30 mM containing 2 mCi/mL [ 3 H]glycine (final specific activity 0.065 mCi/nmol) in an assay volume of 50 mL. Glycine uptake proceeded for 1 h at 27 °C and was stopped by removing unincorporated [ 3 H]glycine and washing as above. Residual wash volume was removed and the cells lysed with 5 mL of 0.1N NaOH. Plates could be stored at this point for up to 48 h in the Cytomat ® 2 C cell incubator without loss of signal. Ultima Gold scintillation cocktail (PerkinElmer) was added (65 mL per well) to plates with a Multidrop, and plates were sealed and allowed to incubate at room temperature for 12 h to stabilize the signal. Radioactivity was quantitated using a PerkinElmer 1450 Microbeta TriLux™ by counting for 30 s per well.
The glycine uptake assay for 4point and 10point concentration response curves was similar to that described above. Fourpoint concentration curves were performed using compounds at 20, 10, 3, and 0.3 mM. For IC 50 value determinations, compounds were diluted by half log steps in DMSO starting from 4mM stocks using a Biomek FX P with a Span8 robotic arm and then diluted into the assay at the indicated concentrations. During clone selection, the time course of glycine uptake was evalu ated using Cytostar T plates as previously described. 21 CHO K1 cells overexpressing GlyT2 were validated for glycine uptake and used similarly to CHOK1/hGlyT1a cells for IC 50 value determinations. Protein determinations were performed using the MPER mammalian protein extraction reagent and the MicroBCA kit (Pierce, Rockford, IL) on groups of satellite wells for conversion of raw counts to specific activity.
DATA ANALYSIS
Screening data were uploaded into ActivityBase (IDBS, Guildford, UK) with the XLfit ® (Version 4.2.2; IDBS) addin to Microsoft Excel and used to convert raw data to percent inhi bition. For IC 50 value determinations, nonlinear regression analysis was fit to a 4parameter equation (equation (1)), where A = bottom of the curve, B = top of the curve, C = log IC 50 , and D = Hill slope, and parameter B was held constant at 100% inhibition.
Additional data manipulation was performed using Spotfire ® software (TIBCO, Somerville, MA). To assess the robustness of the assay performance, the Z′ factor values were calculated as described. 24 Percent inhibition was calculated as shown in equation (2) using the controls provided on each assay plate.
(DPM compound /DPM DMSO Control ) × 100.
(2)
RESULTS

Validation of [ 3 H]glycine uptake assay using CHO-K1/hGlyT1a cells
Cryopreserved CHOK1/hGlyT1a cells were cultured over night in 96 and 384well formats, and the time course for uptake of radiolabeled glycine was evaluated. GlyT1a was determined to be present in the parental CHO cell line as deter mined by PCR (data not shown), and mock transfected CHO cells showed minimal glycine uptake that was superseded by overexpression of human GlyT1a (Fig. 1a) . Glycine uptake was time dependent and linear for 60 and 90 min in 96 and 384well formats, respectively ( Fig. 1b) . Saturation of uptake was observed at times longer than 90 min (data not shown). The greater specific glycine uptake observed in the 96well format as compared to the 384well format was likely due to reduced confluence of the culture in the 384well format as well as reduced specific activity of the [ 3 H]glycine. Finally, the lysis method in either format yielded a greater signal as com pared to the signal observed on Cytostar T plates.
Saturation kinetics was observed with increasing substrate concentration, whereas background glycine uptake in the pres ence of 8 mM sarcosine was linear (Fig. 2) . The Michaelis constant, K m , was similar in cells derived from cryopreserved stocks or from continuous culture ( Table 1 ). In addition, the K m value (20 ± 5 mM) was comparable to that reported using a SPA platebased method for glycine uptake in JAR cells (K m = 27 ± 3 mM), a cell line that endogenously expresses GlyT1a. 17 Direct comparison of the K m value in CHOK1/hGlyT1a cells using either the lysis method or in the SPA platebased method fell within an acceptable range (2.5fold change). However, the platebased SPA method yielded a 32fold lower V max value when compared to the lysis method, which was consistent with observations made in the time course. This may be due, in part, to the low efficiency of counting tritium on Cytostar T plates (manufacturer's literature). Cryopreserved cells maintained uptake activity similar to cells in continuous culture as deter mined in the lysis method, rendering similar V max values in the 96 and 384well format.
Sarcosine, ALX5407, and (S,S)SSR504734 have been described as GlyT1 inhibitors 20, 25 and were employed as refer ence compounds to further validate the use of cryopreserved cells expressing GlyT1 in the 384well format. The inhibition curves fit well to the standard 4parameter equation with Hill slopes that were close to unity (Fig. 3) . The lysis assay method was suitable for determining IC 50 values over a broad range of compound potencies between 0.6 nM and 40 mM ( Table 2) . The assay could readily distinguish between a racemic mixture of SSR504734 and the purified single active isomer (S,S)SSR504734. The IC 50 values determined using cryopre served cells were in agreement with values determined in continuously cultured cells in the 96well format ( Table 2) . Compounds sel ective for other SLC6 transporters were inac tive against GlyT1 activity, including Org25543 (GlyT2), methylphenidate (DAT), nisoxetine (NET), NO711 (GAT), and citalopram (SERT) (data not shown). These data indicate that the use of cryopreserved CHOK1/hGlyT1a cells in the 384well format was feasible for screening.
The quality of the screening data on each plate was assessed by calculation of a Z′ factor, 24 which is a measure of both the dynamic range and the variability inherent in the assay. The positive, negative, and reference compound controls from 1 sample 384well plate are shown in Figure 4a . The outer wells containing the controls used for assessing the Z′ factor on future screening plates accurately reflected the activity of interior wells, which is important to consider when using the Z′ factor as a criterion for rejecting whole plates during screening. 26 The dynamic range of this lysis method was good, with a signalto background ratio that was typically in the range between 20 and 30fold throughout the screen. The variability (percent coefficient of variation) around the positive controls ranged 55 ± 2 (3) 6.5 ± 0.1 (3) (cryopreserved) Cytostar T SPA method K m and V max values for glycine uptake in CHOK1/hGlyT1a were determined for cells in continuous culture and from cryopreserved stocks in 96 and 384well formats. Data are shown as the mean ± SEM, and the number of trials is indicated in parentheses. between 9% and 18%. Each screening plate carried 12 wells of a reference GlyT1 inhibitor at a concentration equal to its IC 50 value. The average percent inhibition value for the refer ence compound across the entire screen (457 plates) was 56% ± 11%. This control was used to evaluate that appropriate vol umes of test compounds were delivered to the assay plate by the robotics.
A screening campaign of 118,000 compounds selected from the Cephalon corporate collection was initiated using cryopre served cells in the 384well format. Compounds were screened at a final concentration of 10 mM. The Z′ factor for each plate in the screen is shown in Figure 4b . The average Z′ factor was 0.56 ± 0.11, and a cutoff of 0.45 was used to reject individual plates from the analysis. Of the 457 plates attempted in the screen, 33 plates (7%) failed this criterion, indicating that this assay was robust and dependable. Testing of these 457 plates was accomplished over 20 screening days, with the bulk of the screening occurring over 6 days. Processing of up to 60 × 384 well plates per day was achieved.
The inhibition values for test compounds showed a normal distribution curve centered around 0% inhibition (Fig. 5) . Com pounds with a percent inhibition that was greater than 3 stan dard deviations above the average were selected as positive for GlyT1 inhibition. This subset represented 4556 compounds, and the percent inhibition values for these compounds were all 50% and above.
Due to the large number of positive compounds, a post screening triage process was used to facilitate confirmation of IC 50 values for GlyT1 reference inhibitors were determined in CHOK1/hGlyT1a cells in continuous culture and from cryopreserved stocks in 96 and 384well formats. Data are shown as the mean ± SEM of 3 or more independent trials. screening results as well as to eliminate less potent compounds from future analyses. Positive compounds were taken forward into 4point concentrationresponse curves performed at 20, 10, 3, and 0.3 mM. Compounds that showed >40% inhibition at 10 mM were considered to confirm their initial identification, which yielded a 68% confirmation rate (3098 compounds). The 4point concentrationresponse curves were used to parse com pounds positive for GlyT1 inhibition into 2 groups (Fig. 6) . The purpose of the algorithm was to eliminate compounds that would show a sharp decline in activity across the concentration curve. This compound profile would be associated with an estimated IC 50 value greater than 10 mM and a steep Hill slope. These undesirable compounds included those that showed greater than 70% inhibition of glycine uptake at 20 mM but demonstrated less than 50% inhibition at 10 mM. These com pounds were removed from further consideration.
The desirable compounds showed greater than 70% inhibi tion at 20 mM and greater than 50% inhibition at 10 mM, with concentrationdependent responses at 3 and 0.3 mM, and were accepted as confirmed. Compounds with less than 70% inhibi tion at 20 mM but greater than 50% inhibition at 10 mM were accepted when concentrationdependent responses at 3 and 0.3 mM were evident. This paradigm allowed for elimination of more than 52% of the singlepoint positive compounds and reduced the burden in the next round of assays.
Because the primary assay was a cellbased functional assay, an additional assay was necessary to exclude compounds that nonspecifically inhibited glycine uptake. Nonspecific inhi bition of glycine uptake could include compounds that were toxic to cells or compounds that affected the CHO cell back ground in some nonspecific manner. For this purpose, GlyT2 was selected as a filter because activity of compounds at this closely related transporter was undesirable, and as it was expressed in the same CHO cell background, it served to detect nonspecific mechanisms of interference. In this paradigm, compounds that inhibited both transporters were eliminated due to lack of specificity of any type. IC 50 values were deter mined for both GlyT1 and GlyT2 activity using 10point concentrationresponse curves in the 384well format. Desirable compounds lacked potency at GlyT2 (IC 50 > 7 mM) while retaining good potency at GlyT1 (IC 50 < 3 mM). These criteria led to the identification of 300 compounds that were organized into chemical families and served as a starting point for hitto lead activities. Select compounds were resynthesized, and their potency was confirmed in a glycine uptake assay validated using rat brain tissue slices, as well as in the original recombi nant cell line used for screening (data not shown).
DISCUSSION
Neurotransmitter transporters are targets for development of smallmolecule therapeutics for CNS disorders such as attention deficit hyperactivity disorder, pain, epilepsy, and schizophre nia. 27 The standard assay for transporter function is to follow uptake of a radiolabeled substrate into intact cells that express the transporter of interest endogenously or recombinantly. 28, 29 Although these assays are well established, previously described methods suffered from several drawbacks for handling large numbers of compounds for testing. These drawbacks include the use of lowdensity assay formats in 24 and 96well plates, multiple wash steps, cell lysis, and addition of scintillation cocktail. The results presented herein demonstrated that adapt ing the standard radiolabeled glycine uptake method to a 384 well plate format renders a robust and reproducible assay that is compatible with standard laboratory automation. This method was amenable to screening moderate numbers of compounds, as well as for performing large numbers of concentration response curves.
The difficulties in preparing quantities of ontime cells for screening were addressed by cryogenically banking the required amount of CHOK1/hGlyT1a cells in advance of screening. Scaleup of the cells in cell factories was accomplished in 9 days and generated a large number of cells (7 × 10 9 ) of the same passage, which eliminated changes in GlyT1a expression level that could potentially occur with extended passage number. Cell handling by simply thawing and diluting cells into the necessary volume and immediately plating into the 384well format was straightforward. Because cells were only cultured overnight, strict sterility was not maintained.
Cryopreserved cells performed similarly to cells grown in continuous culture. The K m value of the transporter for glycine was maintained, and the activity (V max ) of the transporter was comparable between the growth conditions. In addition, the pharmacology of GlyT1 inhibitors with a range of potency between 0.6 nM and 42 mM was similar under both cell growth conditions.
Comparison of the pharmacology of reference GlyT1 inhib itors determined in the 384well format using automation agreed well with previous reports. The IC 50 value for sarcosine was determined to be 39 ± 5 mM in the 384well format and agrees with reported IC 50 values ranging between 9 mM for GlyT1c transfected in quail fibroblasts 20 and 86 mM in rat C6 glioma cells. 25 There was a difference for (S,S)SSR504734, which in the present assay format yielded an IC 50 value of 95 ± 8 nM, as compared to the reported value of 18 nM in SKNMC cells. This discrepancy may be due to the use of a different cell lines or to lower expression levels of endogenous transporter in SKNMC cells. 30 The IC 50 value for ALX5407 (0.7 ± 0.2 nM) agreed reasonably with a previously reported value of 2.8 nM in JAR cells determined using the SPA platebased method. 17 The current assay was adapted to liquidhandling robotics to reduce effort on several laborintensive steps. Typically, cells are washed to remove culture media prior to adding test compounds and substrate and then again to remove substrate to stop the reaction. Integrating a BioTek cell washer into the Biomek workstation facilitated these wash steps. The worksta tion was equipped with SAMI scheduling software, which maintained the identical protocol with similar incubation times for all plates progressing through the assay. Scheduling soft ware also increased the efficiency of the assay process because it allows for interleaving of various activities. Due to the stable endpoint of the assay, large numbers of assay plates were han dled throughout the evening and processed the following morn ing. Addition of scintillation cocktail was performed with a Multidrop, but plate sealing and loading into the counter were processes that were not automated because the plate counter was not integrated to the Biomek workstation. The slowest step in the assay process was the final step of counting radioactivity, with a throughput of 3.5 plates per hour.
The lysis method described herein compares favorably to other types of assay technologies used to evaluate GlyT1 inhi bitors, including SPA and FLIPR membrane potential assays. A platebased SPA for analysis of GlyT1 activity has been described. 17 SPA assays are homogeneous with a mixandread format, which is an advantage over the lysis method. However, several potential drawbacks were encountered in the process of developing a higher throughput SPA assay. SPA assays are typically performed in 96well format, and 384well SPA plates have only recently become available. The signal generated on the 384well SPA plate was not as robust as compared to the 96well SPA plate (data not shown). The lysis method in the 384well format yields a higher signal while using less radioac tivity than does the 96well SPA plate (Fig. 1a,b and Table 1 ). In addition to reduced radiolabel usage, advantages of the 384 well format include less plate handling and reformatting while analyzing greater numbers of compounds per unit time. Another issue with transporter assays using SPA technology is that the signal begins to degrade after 2 h and raises the pragmatic con cern of plate reading and rereading during a large screening campaign (unpublished observations). SPA plates tend to use higher concentrations of tritium (610 mCi/mL), which raises the cost of the screen in addition to the higher cost of the plates. FLIPR membrane potential assays have several advantages as they are homogeneous, nonradioactive, and compatible with the 384well format. However, the confirmation rate for FLIPR was inferior to that observed for the lysis method. A FLIPR assay used in screening for GlyT2 inhibitors confirmed 14 out of 139 positive compounds (10%), 19 whereas the current screening method confirmed 3098 positives of the original 4556 positives (68%). Thus, the value of the lysis method includes improved cost, reduced radioactivity usage, and superior confirmation rate as compared to other methods.
The postHTS compound triage protocol was designed to efficiently identify compounds with satisfactory concentration response characteristics and specific inhibition of GlyT1. 6 . Schema for the decision matrix for the determination of confirmed positive compounds. The primary highthroughput screen ing campaign screened approximately 118,000 compounds with the initial cutoff at 50% inhibition (+3 SD from the mean). Positive com pounds were confirmed with a 4point concentrationresponse curve followed by selectivity for GlyT1 over GlyT2. The schema allowed for the rapid identification of 300 compounds that could be classified into several families of structures with a range of potencies within each family.
